Natural Course and Treatment of Hepatitis D Virus Infection
Hepatitis D virus (HDV) is a subviral satellite with hepatitis B virus (HBV) as its natural helper virus. After entry into hepatocytes, it utilizes host cellular enzymes to replicate by a double-rolling-circle mechanism. HDV is most often transmitted by contact with contaminated blood and body fluid...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2006-01-01
|
Series: | Journal of the Formosan Medical Association |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0929664609601728 |
id |
doaj-a29bbba80c5b445f923f6e09f75fda57 |
---|---|
record_format |
Article |
spelling |
doaj-a29bbba80c5b445f923f6e09f75fda572020-11-24T23:28:11ZengElsevierJournal of the Formosan Medical Association0929-66462006-01-011051186988110.1016/S0929-6646(09)60172-8Natural Course and Treatment of Hepatitis D Virus InfectionTing-Hui Hsieh0Chun-Jen Liu1Ding-Shinn Chen2Pei-Jer Chen3Department of Medicine, Maimonides Medical Center, New York, USADivision of Gastroenterology, Department of Internal Medicine, Taipei, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Taipei, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Taipei, TaiwanHepatitis D virus (HDV) is a subviral satellite with hepatitis B virus (HBV) as its natural helper virus. After entry into hepatocytes, it utilizes host cellular enzymes to replicate by a double-rolling-circle mechanism. HDV is most often transmitted by contact with contaminated blood and body fluid, similar to HBV infection. Approximately 5% of the global HBV carriers are coinfected with HDV, leading to a total of 10-15 million HDV carriers worldwide. HDV infection can occur concurrently with HBV infection (coinfection) or in a patient with established HBV infection (superinfection). The pathogenesis of HDV remains controversial. A decline in the prevalence of both acute and chronic hepatitis D (CHD) has been observed worldwide. At present, therapy for chronic HDV infection is by the use of interferon-a. Compared to chronic hepatitis B or C, CHD treatment requires a higher dosage and a longer duration of treatment, and post-treatment relapses are common. In order to prevent the progression of CHD and its related morbidity and mortality, more effective treatments are needed.http://www.sciencedirect.com/science/article/pii/S0929664609601728genotypehepatitis B virushepatitis D virusseroepidemiologytreatment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ting-Hui Hsieh Chun-Jen Liu Ding-Shinn Chen Pei-Jer Chen |
spellingShingle |
Ting-Hui Hsieh Chun-Jen Liu Ding-Shinn Chen Pei-Jer Chen Natural Course and Treatment of Hepatitis D Virus Infection Journal of the Formosan Medical Association genotype hepatitis B virus hepatitis D virus seroepidemiology treatment |
author_facet |
Ting-Hui Hsieh Chun-Jen Liu Ding-Shinn Chen Pei-Jer Chen |
author_sort |
Ting-Hui Hsieh |
title |
Natural Course and Treatment of Hepatitis D Virus Infection |
title_short |
Natural Course and Treatment of Hepatitis D Virus Infection |
title_full |
Natural Course and Treatment of Hepatitis D Virus Infection |
title_fullStr |
Natural Course and Treatment of Hepatitis D Virus Infection |
title_full_unstemmed |
Natural Course and Treatment of Hepatitis D Virus Infection |
title_sort |
natural course and treatment of hepatitis d virus infection |
publisher |
Elsevier |
series |
Journal of the Formosan Medical Association |
issn |
0929-6646 |
publishDate |
2006-01-01 |
description |
Hepatitis D virus (HDV) is a subviral satellite with hepatitis B virus (HBV) as its natural helper virus. After entry into hepatocytes, it utilizes host cellular enzymes to replicate by a double-rolling-circle mechanism. HDV is most often transmitted by contact with contaminated blood and body fluid, similar to HBV infection. Approximately 5% of the global HBV carriers are coinfected with HDV, leading to a total of 10-15 million HDV carriers worldwide. HDV infection can occur concurrently with HBV infection (coinfection) or in a patient with established HBV infection (superinfection). The pathogenesis of HDV remains controversial. A decline in the prevalence of both acute and chronic hepatitis D (CHD) has been observed worldwide. At present, therapy for chronic HDV infection is by the use of interferon-a. Compared to chronic hepatitis B or C, CHD treatment requires a higher dosage and a longer duration of treatment, and post-treatment relapses are common. In order to prevent the progression of CHD and its related morbidity and mortality, more effective treatments are needed. |
topic |
genotype hepatitis B virus hepatitis D virus seroepidemiology treatment |
url |
http://www.sciencedirect.com/science/article/pii/S0929664609601728 |
work_keys_str_mv |
AT tinghuihsieh naturalcourseandtreatmentofhepatitisdvirusinfection AT chunjenliu naturalcourseandtreatmentofhepatitisdvirusinfection AT dingshinnchen naturalcourseandtreatmentofhepatitisdvirusinfection AT peijerchen naturalcourseandtreatmentofhepatitisdvirusinfection |
_version_ |
1725550485109211136 |